Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07588568 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis

Study acronym: ATUNE
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Primary endpoints: details revised at 1 of 1 entry · Start date changed from estimate of Oct 2026 to Sep 30, 2026 · Eligibility criteria expanded, about 33 words · 2 more Show 5 more changesShow less
    • Primary endpoints: details revised at 1 of 1 entry
    • Start date changed from estimate of Oct 2026 to Sep 30, 2026
    • Eligibility criteria expanded, about 33 words
    • Secondary endpoints: details revised at 6 of 6 entries
    • Site details revised at 2 of 2 sites
  2. Start date: Jul 2026 to Oct 2026 Collaborators: 2 to 5v2 Show 1 more changeShow less
    • Collaborators: 2 to 5

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this study is to find out if a medication called upadacitinib can help treat a condition called Eosinophilic Esophagitis (EoE). The main question it aims to answer are: \- Does upadacitinib in addition to topical corticosteroids help reduce EoE disease activity? Participants will: * Take upadacitinib or placebo every day for 12 weeks, followed by 12 weeks of upadacitinib * Fill out surveys and answer health questions * Visit the clinic every 4 weeks for checkups and tests
Trial Details
NCT Number NCT07588568
Lead Sponsor University of North Carolina, Chapel Hill
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), AbbVie, University of California, San Diego, La Jolla Institute for Immunology, Duke University
Conditions EoE, Eosinophilic Esophagitis, Eosinophilic Esophagitis (EoE)
Enrollment 52 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov